Vertex Pharmaceuticals Incorporated (VRTX34) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Vertex Pharmaceuticals Incorporated BRL 93.52, price BRL 85.86, upside +8.9%, quality 80 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
How to read this chart
60‑month range R$29.16 – R$622.01 · fair‑value band R$57.14 – R$149.94 · the R$85.86 price screens below the R$93.52 fair value. Dashed = 300-day average. As of Sep 29, 2026.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Show more
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Stock analysis
Vertex Pharmaceuticals Incorporated (VRTX34) currently trades at R$85.86, while our model-based Fair Value estimate is R$93.52, so the stock looks roughly fairly valued today (gap 8.2%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of R$63.92 per share, and 1 of the 24 models we run sit above the R$85.86 price.
Bear case: the Economic Profit group reads lowest at R$23.10, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: R$57.14 (bear) to R$149.94 (bull), the price of R$85.86 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Vertex Pharmaceuticals Incorporated reported revenue of $12.0B in FY2025 versus $7.6B in FY2021, a compound +12.2%/yr. Reported net income was $4.0B in FY2025, compounding +14.0%/yr from FY2021.
Key figures
Market cap R$615B (≈ $118B) · P/E ratio 27.8 · P/S ratio 9.15 · EPS (TTM) R$21.81 · Net margin 32.9% · Return on equity 24.2% · Return on assets (EBIT) 15.3% · Operating margin 38.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 86% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 9%, VRTX34 screens richer than that median.
Fair Value models
Bear R$57.14Fair Value R$93.52Bull R$149.94
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$16.49 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.2%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+11.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.46% → 35%
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vertex Pharmaceuticals Incorporated (VRTX34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$93.52 versus a price of R$85.86, about +9% upside (fairly valued).
What is the fair value of VRTX34?
Our model-based fair value for Vertex Pharmaceuticals Incorporated is R$93.52 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$85.86.
What is the quality score of VRTX34?
Vertex Pharmaceuticals Incorporated has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vertex Pharmaceuticals Incorporated (VRTX34)?
Our model-based price target is the fair value of R$93.52 (as of Sep 29, 2026) from 24 valuation models. Cautious scenario R$57.14, optimistic scenario R$149.94. It is a calculation from audited fundamentals, not an analyst target.
What is the Vertex Pharmaceuticals Incorporated stock forecast for 2026?
Our models put fair value at R$93.52, about +9% upside versus a price of R$85.86 (fairly valued). Cautious scenario R$57.14, optimistic scenario R$149.94. The calculation is refreshed regularly with new filings.
What is the revenue of Vertex Pharmaceuticals Incorporated (VRTX34)?
Vertex Pharmaceuticals Incorporated reported trailing-twelve-month revenue of about $12.2B (latest available figure, as of Sep 29, 2026).
What is the intrinsic value of Vertex Pharmaceuticals Incorporated (VRTX34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vertex Pharmaceuticals Incorporated it is R$93.52 per share (as of Sep 29, 2026), against a price of R$85.86. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Vertex Pharmaceuticals Incorporated stock overvalued or undervalued in 2026?
As of Sep 29, 2026, VRTX34 trades below its calculated fair value: price R$85.86, fair value R$93.52, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VRTX34?
No. The price is what the market pays today (R$85.86); the fair value is what the company's own numbers justify (R$93.52). For Vertex Pharmaceuticals Incorporated the two are R$7.66 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vertex Pharmaceuticals Incorporated worth?
The market values Vertex Pharmaceuticals Incorporated at about R$615B (market capitalisation, as of Sep 29, 2026). Per share that is R$85.86; our models calculate a fair value of R$93.52 per share.
What do the bullish and bearish scenarios say about VRTX34?
Our models span a range for Vertex Pharmaceuticals Incorporated: cautious scenario R$57.14, base R$93.52, optimistic R$149.94 per share (as of Sep 29, 2026, price R$85.86). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is VRTX34 from its 52-week high?
Vertex Pharmaceuticals Incorporated trades at R$85.86, about 86% below its 52-week high of R$622.01 and 32% above the low of R$65.18 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of R$93.52 is for.
Which stocks are comparable to Vertex Pharmaceuticals Incorporated?
From the same area (Healthcare) we also value Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vertex Pharmaceuticals Incorporated stock attractive at the current price?
The data as of Sep 29, 2026: price R$85.86, calculated fair value R$93.52 (+9%), Quality Score 80/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VRTX34 calculated?
We run Vertex Pharmaceuticals Incorporated through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$93.52, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Vertex Pharmaceuticals Incorporated currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vertex Pharmaceuticals Incorporated (VRTX34)?
The closing price on Sep 30, 2026 was R$85.86. Our model-based fair value is R$93.52, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vertex Pharmaceuticals Incorporated right now?
The model range is unusually wide (R$57.14 to R$149.94). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of Vertex Pharmaceuticals Incorporated
How large is the market capitalisation of Vertex Pharmaceuticals Incorporated (VRTX34)?
The market capitalisation of Vertex Pharmaceuticals Incorporated is R$615B (≈ $118B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Vertex Pharmaceuticals Incorporated (VRTX34)?
The price-to-earnings ratio of Vertex Pharmaceuticals Incorporated is 27.8 (as of Jul 17, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Vertex Pharmaceuticals Incorporated (VRTX34)?
The price-to-sales ratio of Vertex Pharmaceuticals Incorporated is 9.15 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vertex Pharmaceuticals Incorporated (VRTX34)?
Earnings per share at Vertex Pharmaceuticals Incorporated are R$21.81 (price ÷ EPS = P/E 27.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vertex Pharmaceuticals Incorporated (VRTX34)?
The net margin of Vertex Pharmaceuticals Incorporated is 32.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vertex Pharmaceuticals Incorporated (VRTX34)?
The return on equity (ROE) of Vertex Pharmaceuticals Incorporated is 24.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vertex Pharmaceuticals Incorporated (VRTX34)?
On an EBIT basis the return on assets of Vertex Pharmaceuticals Incorporated is 15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vertex Pharmaceuticals Incorporated (VRTX34)?
The operating margin of Vertex Pharmaceuticals Incorporated is 38.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vertex Pharmaceuticals Incorporated (VRTX34)?
Revenue at Vertex Pharmaceuticals Incorporated is growing +7.8% versus a year earlier (3y avg +10.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vertex Pharmaceuticals Incorporated (VRTX34)?
Earnings per share at Vertex Pharmaceuticals Incorporated are growing +61.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vertex Pharmaceuticals Incorporated (VRTX34) generate?
The free cash flow of Vertex Pharmaceuticals Incorporated is $3.2B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
